首页|期刊导航|中华医学杂志（英文版）|A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer

A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer

WEI Hai-bo HU Jing SHANG Li-hua ZHANG Yun-yan LU Fei-fei WEI Min YU Yan

中华医学杂志（英文版）2012，Vol.125Issue(16)：2902-2907,6.

中华医学杂志（英文版）2012，Vol.125Issue(16)：2902-2907,6.DOI:10.3760/cma.j.issn.0366-6999.2012.16.019

A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer

WEI Hai-bo ¹HU Jing ²SHANG Li-hua ³ZHANG Yun-yan ³LU Fei-fei ⁴WEI Min ³YU Yan³

作者信息

1. Department of Oncology Medicine , Third Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, China
2. Department of Oncology Medicine, Chifeng Municipal Hospital,Chifeng, Inner Mongolia 024000, China
3. Department of Oncology Medicine , Third Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, China
4. Department of Gynecological Radiotherapy , Third Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150081, China
折叠

摘要

Abstract

Background Platinum-based regimens are used as standard first-line chemotherapy in non-small cell lung cancer (NSCLC) patients.To study if pharmacogenetic approach may allow a tailored selection of platinum chemotherapy for advanced NSCLC,we performed a meta-analysis to compare chemosensitivity to platinum with different ERCC1 C118T/MDR1 C3435T single-nucleotide polymorphism (SNP).Methods Relevant studies were identified by searching the PubMed,Embase,Cochrane,OVID,Springer,EBSCO and CNKI databases.Inclusion criteria were patients with advanced NSCLC who received platinum-based chemotherapy,an evaluated polymorphism of ERCC/MDR1 and overall response rate.We excluded duplicate publications,letters and review articles.The RevMan 4.2 and STATA 11 package were used to do comprehensive quantitative assessment.Results A total of 11 studies were included in this meta-analysis.For studies evaluating ERCC1 C118T,test for heterogeneity was done (x2=13.41,P=0.1),and the odds ratio (OR) for the wild-type C/C genotype versus the heterozygous C/T and T/T genotypes was 1.50 (95％ CI 1.09-2.06,P=-0.01).In four studies evaluating MDR1 polymorphism,test for heterogeneity was also done (x2=3.22,P=0.36),and the OR for the wild-type C/C genotype versus the heterozygous C/T and T/T genotypes was 2.30 (95％ CI 1.44-3.68,P=0.0005).Conclusions The results indicated that platinum-based chemotherapy sensitivity was significantly associated with polymorphism of ERCC1 C118T and MDR1 C3435T SNP.In further perspective studies,the ERCC1/MDR1 SNPs might serve as simple and less invasive biomarkers for personalized chemotherapy with platinum-based anticancer drugs.

关键词

non-small-cell lung cancer/ERCC1/MDR1, platinum-based/chemotherapy/meta-analysis

Key words

non-small-cell lung cancer/ERCC1/MDR1, platinum-based/chemotherapy/meta-analysis

引用本文复制引用

WEI Hai-bo,HU Jing,SHANG Li-hua,ZHANG Yun-yan,LU Fei-fei,WEI Min,YU Yan..A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer[J].中华医学杂志（英文版）,2012,125(16):2902-2907,6.

基金项目

This study was supported by a grant from the National Natural Science Foundation o f China (No.C171003) and Doctoral Fund of Ministry of Education of China. （No.C171003）

中华医学杂志（英文版）

OACSCDCSTPCDMEDLINESCI

ISSN：0366-6999

访问量0

下载量0

段落导航